Publish Date: 
Mon, 05/07/2018 - 21:15

Initiating therapy: information on blood typing

Interference with indirect antiglobulin test (indirect Coombs test)

DARZALEX binds to CD38, which is found at low levels on red blood cells
(RBCs), and may result in a false positive indirect Coombs test.1

  • DARZALEX-mediated positive indirect Coombs test may persist for up to 6 months after the last DARZALEX infusion.
  • If a patient’s history of receiving DARZALEX is not clearly communicated to the blood bank, delays in the release of blood products for transfusion may occur.
  • If an emergency transfusion is required, non-crossmatched, ABO/RhD-compatible RBCs can be given, per local blood bank practices.

To ensure patients receive a timely transfusion:

Type and screen patients prior to starting DARZALEX. In the event of a planned transfusion, notify blood transfusion centres of this interference with indirect antiglobulin tests. If an emergency transfusion is required, non-cross-matched ABO/RhD-compatible RBCs can be given per local blood bank practices.1

1. DARZALEX® Product Information.

Resources

PBS Information

PBS Information:
This product is not listed
on the PBS.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from http://www.janssen.com.au/Darzalex_PI) Reference: 1. DARZALEX® Product Information. DARZALEX® is a registered trademark of Janssen-Cilag. Further information is available on request from Janssen-Cilag Pty Ltd, ABN 47 000 129 975, 1-5 Khartoum Road, Macquarie Park NSW 2113. Ph: 1800 226 334. CP-57298 DAR0078 Date prepared April 2018.